ArticleJournal of movement disorders2017
Sleepiness and Depression in Parkinson's Disease Patients Treated with Ropinirole and Levodopa.
Article in Journal of movement disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Sleep Disorders and Cognitive Dysfunctions in Parkinson's Disease: A Meta-Analytic Study.Neuropsychology review · 2021Pooled it
- The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis.Medicine · 2021Pooled it
- Longitudinal risk factors for developing depressive symptoms in Parkinson's disease.Journal of the neurological sciences · 2021Pooled it
- Associations between non-motor symptoms and patient characteristics in Parkinson's disease: a multicenter cross-sectional study.Frontiers in aging neuroscience · 2023Article
- Excessive Daytime Sleepiness in Parkinson's Disease.Nature and science of sleep · 2022Review
- Effects of Deep Brain Stimulation on Sleep-Wake Disturbances in Patients with Parkinson's Disease: A Narrative Review.Current neuropharmacology · 2021Review
- An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression.Frontiers in psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson's disease (PD) with a large population.
methodsWe conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson's Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).
resultsFour-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression.
conclusionOur large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.